The Lancet· Brian M Slomovitz, Jianqing Zhu, Rutie Yin, Floor Backes, Mariusz Bidziński, Lucy Gilbert, Lyndsay J Willmott, Kosei Hasegawa, Jae-Weon Kim, Judith R Kroep, Ignacio Romero, Murat Gultekin, Peng-Hui Wang, Sally Baron-Hay, Jaroslav Klát, Ora Rosengarten, Maggie Polignano, Marcela Berrios, Karen Cadoo, Heini Lassus, Beata Maćkowiak-Matejczyk, Domenica Lorusso, Anna K L Reyners, Elizabeth R Burton, Vicky Makker, Lili Yao, Robin Meng, Robert Orlowski, Sandro Pignata·· 3 小时前评分77
KEYNOTE-C93中期分析显示一线pembrolizumab较卡铂联合紫杉醇改善PFS
[Articles] First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial
导读
KEYNOTE-C93中期分析显示，一线pembrolizumab较卡铂联合紫杉醇在错配修复缺陷的晚期或复发性子宫内膜癌中实现统计学显著且具临床意义的PFS改善。KEYNOTE-C93/GOG-3064/ENGOT-en15试验中，pembrolizumab组总体及3级或以上治疗相关不良事件更少。研究未比较pembrolizumab单药与当前标准治疗免疫治疗联合化疗。
来源：The Lancet · thelancet.com